EMD Serono is the biopharmaceutical business of Merck KGaA (Darmstadt, Germany) in the USA and Canada.
EMD Serono’s diversified oncology and immuno-oncology pipeline includes multiple projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient needs. Our dedicated R & D translational innovation platforms are focused on using emerging science and tools to apply the principles of precision medicine to develop personalized therapies that may optimize treatment outcomes for patients.
As part of the biopharmaceutical business of Merck KGaA (Darmstadt, Germany), we are uniquely positioned to draw from the resources and experiences of our parent company in the area of oncology. In the USA, we aim to continue our strong legacy of bringing best-in-class products and solutions to patients as we move into oncology.